– FRANCE, Paris – During its meeting held on March 5, 2014, the Board of Directors of Stallergenes (Paris:GENP) announced the appointment of Christian CHAVY as Chief Executive Officer, to replace Roberto GRADNIK. This appointment will be effective on March 31, 2014.
The appointment of Christian CHAVY will enable the Group to pursue its strategy and to support Stallergenes in promising markets for immunotherapy, with a particular focus on the US market.
Roberto GRADNIK will ensure a smooth transition and will provide consultancy services to the Board of Directors during a four-month transitional period.
Patrick LANGLOIS, Chairman of the Board of Directors, commented: “On behalf of the Board of Directors, I would like to warmly thank Roberto GRADNIK, who has successfully implemented a new organization adapted to the new operational challenges faced by the Group. Under his leadership, the Group made a major breakthrough, with the preparation and submission of the application for commercial authorisation of Oralair ® tablets in the US, which is currently reviewed by the FDA, and the definition of a long-term strategy, with a particularly strong focus on international markets. The appointment of Christian CHAVY represents a continuation of this strategy. His recognised management skills, his international experience and considerable knowledge of the pharmaceuticals industry will enable Stallergenes to continue its expansion into promising markets for immunotherapy and in particular to ensure the success of Oralair ® in the US market.”
In 2010, Christian CHAVY joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals (USA, Europe, Japan and rest of the world). Prior to joining Actelion, he was Vice President at the reproductive medicine strategic unit of Serono in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY is a graduate of ESSEC and Institut de Contrôle de Gestion de Paris (ICG).
STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, it has been continuously expanding the existing frontiers of science in order to provide allergy patients with more effective long lasting therapeutic options. Thanks to its innovation strategy, fueled by investments amounting to around 20% of total annual revenues as well as external cooperations, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.
STALLERGENES operates in 20 countries and employs over 1,000 people. In 2013, the Company generated total revenues of € 248 million, and more than 500,000 patients were treated with STALLERGENES products.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.